HC Wainwright Has Bearish Forecast for FENC Q1 Earnings

Adherex Technologies Inc. (NASDAQ:FENC) – Analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of Adherex Technologies in a research note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.02) for the quarter, down from their previous forecast of $0.07. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies’ Q2 2026 earnings at $0.05 EPS, FY2026 earnings at $0.31 EPS, Q1 2027 earnings at $0.17 EPS and Q2 2027 earnings at $0.22 EPS.

Adherex Technologies (NASDAQ:FENC) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.21). Adherex Technologies had a negative net margin of 22.62% and a negative return on equity of 183.18%. The company had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.75 million.

FENC has been the subject of a number of other research reports. Wall Street Zen cut shares of Adherex Technologies from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Zacks Research cut shares of Adherex Technologies from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adherex Technologies in a report on Thursday, January 22nd. B. Riley Financial started coverage on shares of Adherex Technologies in a research note on Thursday, February 12th. They issued a “buy” rating and a $16.00 target price for the company. Finally, Piper Sandler assumed coverage on Adherex Technologies in a report on Friday, January 9th. They issued an “overweight” rating and a $18.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, Adherex Technologies presently has an average rating of “Moderate Buy” and an average target price of $15.25.

Adherex Technologies Stock Performance

Shares of NASDAQ FENC opened at $6.15 on Wednesday. Adherex Technologies has a 52-week low of $4.68 and a 52-week high of $9.92. The business has a fifty day moving average of $7.77 and a two-hundred day moving average of $8.04. The stock has a market cap of $211.99 million, a PE ratio of -18.09 and a beta of 0.75.

Insider Transactions at Adherex Technologies

In related news, Director Rosty Raykov sold 10,349 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $7.76, for a total transaction of $80,308.24. Following the transaction, the director owned 98,477 shares in the company, valued at $764,181.52. This represents a 9.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC purchased a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned 0.05% of Adherex Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Key Headlines Impacting Adherex Technologies

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: Analysts give a “Moderate Buy” consensus for Adherex, which can support the stock as investors weigh the outlook versus the recent miss. Article Title
• Positive Sentiment: HC Wainwright issued a multi?quarter and FY2027 outlook that is materially positive (FY2027 EPS forecast of ~$0.96, with Q3/Q4 2027 estimates at $0.26 and $0.30), suggesting significant expected earnings improvement over the next 12–24 months. Analyst Note
• Neutral Sentiment: The company approved inducement stock option awards (377,500 ISOs to 24 new non?executive employees) under Nasdaq rules — signals hiring/retention but also potential future dilution; watch grant strike prices and vesting. Press Release
• Negative Sentiment: Earnings miss: Adherex reported ($0.17) EPS vs. a $0.04 consensus and revenue of $13.78M vs. $14.75M expected — the miss and negative margins/ROE are the primary near?term drivers pushing the stock lower. Listen to the conference call and review the release for management’s commentary on guidance and cost actions. Earnings Transcript Press Release
• Negative Sentiment: HC Wainwright reduced near?term EPS forecasts for Q3 and Q4 2026 (Q3: from $0.19 to $0.12; Q4: from $0.24 to $0.16), which increases short?term uncertainty despite their optimistic longer?term view. Analyst Revision

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.